Effects of a SARS-associated coronavirus vaccine in monkeys.
The causative agent of severe acute respiratory syndrome (SARS) has been identified as a new type of coronavirus. Here, we have investigated the ability of adenoviral delivery of codon-optimised SARS-CoV strain Urbani structural antigens spike protein S1 fragment, membrane protein, and nucleocapsid protein to induce virus-specific broad immunity in rhesus macaques. We immunised rhesus macaques intramuscularly with a combination of the three Ad5-SARS-CoV vectors or a control vector and gave a booster vaccination on day 28. The vaccinated animals all had antibody responses against spike protein S1 fragment and T-cell responses against the nucleocapsid protein. All vaccinated animals showed strong neutralising antibody responses to SARS-CoV infection in vitro. These results show that an adenoviral-based vaccine can induce strong SARS-CoV-specific immune responses in the monkey, and hold promise for development of a protective vaccine against the SARS causal agent.
Gao
Wentao
W
Department of Surgery Molecular, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA.
Tamin
Azaibi
A
Soloff
Adam
A
D'Aiuto
Leonardo
L
Nwanegbo
Edward
E
Robbins
Paul D
PD
Bellini
William J
WJ
Barratt-Boyes
Simon
S
Gambotto
Andrea
A
D000256:Adenoviridae / Q000276:immunology*; D000818:Animals; D000917:Antibody Formation / Q000276:immunology; D015153:Blotting, Western; D017934:Coronavirus / Q000276:immunology*; D000086462:Coronavirus Nucleocapsid Proteins; D004195:Disease Models, Animal; D006801:Humans; D008253:Macaca mulatta; D008992:Monkey Diseases / Q000517:prevention & control / Q000821:virology; D019590:Nucleocapsid Proteins / Q000276:immunology; D045473:Severe acute respiratory syndrome-related coronavirus / Q000276:immunology*; D045169:Severe Acute Respiratory Syndrome / Q000276:immunology / Q000517:prevention & control*; D013601:T-Lymphocytes / Q000276:immunology; D014611:Vaccination / Q000379:methods; D014759:Viral Envelope Proteins / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology* / Q000627:therapeutic use
D000086462:Coronavirus Nucleocapsid Proteins; D019590:Nucleocapsid Proteins; D014759:Viral Envelope Proteins; D014765:Viral Vaccines